Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2015 2
2018 3
2019 1
2020 3
2021 1
2022 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial.
Lorenzon R, Ribet C, Pitoiset F, Aractingi S, Banneville B, Beaugerie L, Berenbaum F, Cacoub P, Champey J, Chazouilleres O, Corpechot C, Fautrel B, Mekinian A, Regnier E, Saadoun D, Salem JE, Sellam J, Seksik P, Vicaut E, Rosenzwajg M, Klatzmann D. Lorenzon R, et al. J Autoimmun. 2024 Apr;144:103172. doi: 10.1016/j.jaut.2024.103172. Epub 2024 Feb 7. J Autoimmun. 2024. PMID: 38330545
Deep immunophenotyping reveals that autoimmune and autoinflammatory disorders are spread along two immunological axes capturing disease inflammation levels and types.
Tchitchek N, Binvignat M, Roux A, Pitoiset F, Dubois J, Marguerit G, Saadoun D, Cacoub P, Sellam J, Berenbaum F, Hartemann A, Amouyal C, Lorenzon R, Mariotti-Ferrandiz E, Rosenzwajg M, Klatzmann D. Tchitchek N, et al. Among authors: lorenzon r. Ann Rheum Dis. 2024 Apr 11;83(5):638-650. doi: 10.1136/ard-2023-225179. Ann Rheum Dis. 2024. PMID: 38182406 Free article.
Pharmacodynamics of regulatory T cells in mice and humans treated with low-dose IL-2.
Churlaud G, Abbara C, Vinot PA, Fourcade G, Ritvo PG, Lorenzon R, Rosenzwajg M, Diquet B, Klatzmann D. Churlaud G, et al. Among authors: lorenzon r. J Allergy Clin Immunol. 2018 Oct;142(4):1344-1346.e3. doi: 10.1016/j.jaci.2018.06.006. Epub 2018 Jun 18. J Allergy Clin Immunol. 2018. PMID: 29920353 Free article. Clinical Trial. No abstract available.
Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol.
Lorenzon R, Mariotti-Ferrandiz E, Aheng C, Ribet C, Toumi F, Pitoiset F, Chaara W, Derian N, Johanet C, Drakos I, Harris S, Amselem S, Berenbaum F, Benveniste O, Bodaghi B, Cacoub P, Grateau G, Amouyal C, Hartemann A, Saadoun D, Sellam J, Seksik P, Sokol H, Salem JE, Vicaut E, Six A, Rosenzwajg M, Bernard C, Klatzmann D. Lorenzon R, et al. BMJ Open. 2018 Aug 30;8(8):e021037. doi: 10.1136/bmjopen-2017-021037. BMJ Open. 2018. PMID: 30166293 Free PMC article.
Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.
Rosenzwajg M, Lorenzon R, Cacoub P, Pham HP, Pitoiset F, El Soufi K, RIbet C, Bernard C, Aractingi S, Banneville B, Beaugerie L, Berenbaum F, Champey J, Chazouilleres O, Corpechot C, Fautrel B, Mekinian A, Regnier E, Saadoun D, Salem JE, Sellam J, Seksik P, Daguenel-Nguyen A, Doppler V, Mariau J, Vicaut E, Klatzmann D. Rosenzwajg M, et al. Among authors: lorenzon r. Ann Rheum Dis. 2019 Feb;78(2):209-217. doi: 10.1136/annrheumdis-2018-214229. Epub 2018 Nov 24. Ann Rheum Dis. 2019. PMID: 30472651 Clinical Trial.
Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.
Rosenzwajg M, Churlaud G, Mallone R, Six A, Dérian N, Chaara W, Lorenzon R, Long SA, Buckner JH, Afonso G, Pham HP, Hartemann A, Yu A, Pugliese A, Malek TR, Klatzmann D. Rosenzwajg M, et al. Among authors: lorenzon r. J Autoimmun. 2015 Apr;58:48-58. doi: 10.1016/j.jaut.2015.01.001. Epub 2015 Jan 26. J Autoimmun. 2015. PMID: 25634360 Free PMC article. Clinical Trial.
13 results